OV PRECISION: A randomized controlled Swiss study to investigate the benefits of a biology-specific cancer therapy for advanced hard-to-treat ovarian cancer.
Résumé de l'étude
In about one in two patients with ovarian cancer, damage in a repair mechanism is shown to be the cause of its development, which ensures that genetic material is correctly renewed in healthy cells (HRD positive). These patients are more likely to develop ovarian cancer but, on the other hand, respond particularly well to standard chemotherapy with carboplatin. Our study OV PRECISION is specifically intended for the other 50%, the HRD negative patients, of whom we already know that they will not respond as well to standard chemotherapy, thus having a poor prognosis and urgently needing better treatment options. We investigate the applicability of an additional treatment recommendation based on comprehensive biological information and discussion in an expert panel. This recommendation is issued by a specialized so-called molecular tumor board, which is intended to support the treating physician in the clinical practice in treating the patient with advanced ovarian cancer. OV PRECISION combines various biological analyses, evaluates the results as a whole, and can suggest the most effective drugs/experimental therapies for each participating ovarian cancer patient, regardless of the standard treatment. In a randomized study, chance decides whether the participant receives an individual treatment recommendation or not. This eliminates systematic errors and achieves a fair distribution. The experimental group receives the recommendation, discusses it with the physician, and may carry out an individual, recommendation-based treatment for a maximum of 42 days. The control group receives no treatment recommendation and therefore receives standard chemotherapy (42 days). OV PRECISION is being conducted at several Swiss hospitals and is set for 2 years. We expect a total of 60 participants.
(BASEC)
Intervention étudiée
Participation in this study lasts 9 weeks and includes, depending on therapy, up to nine study visits including examinations prior to the planned surgery. For routine diagnosis, tumor material is obtained through a biopsy during ultrasound or by draining abdominal fluid or fluid from the lung, which is used, in addition to the normal examination in pathology, for determining the HRD status. To know whether an extensive operation is even reasonable, an initial laparoscopy is performed to assess the extent of the disease. During this operation, tissue samples are taken for analysis. For HRD negative patients, a part of the tumor sample taken here is used for the precise examination of biological properties within the framework of the OV Precision study. HRD positive patients leave the study at this point and receive standard therapy for ovarian cancer, i.e., either the extensive operation or chemotherapy before surgery, depending on the patient's condition and tumor extent. The biology-based individual treatment recommendation by the international expert panel is available to the treating physician and the patient within 2 weeks. An individual, biology-based treatment will be carried out within a time frame of 42 days before the planned surgery. As part of the study visits, a physical examination will be conducted as well as blood count, laboratory values including liver values, electrolytes, kidney values, and the tumor marker CA-125 will be recorded. In addition, participants will be regularly asked about their well-being. This aims to capture the quality of life of the participants and possible side effects of the chosen therapy. The study aims to provide researchers with an indication of a potentially better therapeutic response in HRD negative patients. A better therapeutic response, i.e., a benefit, would manifest in one of the predefined so-called primary (focal) endpoints. This is determined by comparing the number of patients in the experimental arm with those in the control arm at the end of the study regarding their respective treatment responses. For this purpose, tissue examination during the operation is used.
(BASEC)
Maladie en cours d'investigation
Primary disease of epithelial ovarian cancer, in which no homologous recombination deficiency (no HRD) can be detected.
(BASEC)
- ≥ 18 years and newly diagnosed epithelial ovarian cancer (adenocarcinoma of the ovary, peritoneum, and fallopian tube) or ovarian carcinosarcoma with suspected extensive FIGO stage III and IV -Good general condition (ECOG 0-2) and no immediate need for systemic or surgical treatment at the time of diagnosis and up to 2 weeks thereafter -Planned candidate for surgical reduction/removal of tumor mass after 2 treatment cycles (42 days) (BASEC)
Critères d'exclusion
-Poor general condition (ECOG ≥3) or elevated liver and kidney values - Pregnant and breastfeeding women - Any other malignant tumor disease within the last 5 years that may affect the patient's prognosis. - Simultaneous participation in another clinical study for the same indication - Inability to swallow tablets (BASEC)
Lieu de l’étude
Bâle, Berne, Fribourg, St-Gall, Zurich, Autre
(BASEC)
Baden, Thurgau-Frauenfeld
(BASEC)
Sponsor
Swiss GO Trial Group PD André Fedier Spitalstrasse 21 4031 Basel Schweiz
(BASEC)
Contact pour plus d'informations sur l'étude
Personne de contact en Suisse
Prof. Dr. med. Viola Heinzelmann-Schwarz
+41 (0) 61 265 58 83
viola.heinzelmann@clutterusb.chUniversity Hospital Basel
(BASEC)
Informations générales
University Hospital Basel, Head Women's Hospital,
+41 61 3284203;+41 (0)61 265 58 83
viola.heinzelmann@clutterusb.ch(ICTRP)
Informations générales
University Hospital Basel, Head Women's Hospital
+41 61 3284203
viola.heinzelmann@clutterusb.ch(ICTRP)
Informations scientifiques
University Hospital Basel, Head Women's Hospital,
+41 61 3284203;+41 (0)61 265 58 83
viola.heinzelmann@clutterusb.ch(ICTRP)
Nom du comité d'éthique approbateur (pour les études multicentriques, uniquement le comité principal)
Ethikkommission Nordwest- und Zentralschweiz EKNZ
(BASEC)
Date d'approbation du comité d'éthique
14.03.2024
(BASEC)
Identifiant de l'essai ICTRP
NCT06466382 (ICTRP)
Titre officiel (approuvé par le comité d'éthique)
Tumor-Profiling-based Precision Treatment in Ovarian Cancer, a prospectively randomized controlled Swiss trial (OV Precision). (BASEC)
Titre académique
OV PRECISION: A Randomized Controlled Swiss Trial Examining the Benefit of a Tumor- and Patient-specific Cancer Therapy in Ovarian Cancer. (ICTRP)
Titre public
OV Precision: Study Examining the Benefit of a Tumor- and Patient-specific Cancer Therapy (ICTRP)
Maladie en cours d'investigation
Ovarian Neoplasm EpithelialFallopian Tube NeoplasmsOvarian Endometrioid CarcinomaHigh-grade Serous Ovarian Carcinoma (HGSOC) (ICTRP)
Intervention étudiée
Other: Treatment recommendation by molecular tumorboard (mTB) based on tumor profilingDrug: Carboplatin / Paclitaxel Chemotherapy (ICTRP)
Type d'essai
Interventional (ICTRP)
Plan de l'étude
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label). (ICTRP)
Critères d'inclusion/exclusion
Inclusion Criteria:
- Newly diagnosed EOC (adenocarcinoma of the ovary, peritoneum, and fallopian tube)
and carcinosarcoma patients with a suspected FIGO Stage III and IV
- No immediate need of systemic or surgical treatment at time of and until 2 weeks
after diagnosis
- Envisaged surgical candidate for interval debulking after 2 cycles of treatment
- Willing and able to attend the visits, to understand the purpose of the trial and
all trial-related procedures
- ECOG 0-2
- Written informed consent according to national legal and regulatory requirements
prior to any project specific procedures
Exclusion Criteria:
- Elevated liver enzymes (double of normal range: ASAT > 68 U/l ALAT > 82 U/l GGT >
80 U/l)
- Elevated creatinine (double of normal range: >120 mmol/l))
- ECOG =3
- Pregnant or lactating women
- Any other malignancy within the last 5 years which has an impact on the prognosis of
the patient
- Inability to swallow tablets
- Concurrent participation in another clinical trial on the same indication
- Any other serious underlying medical, psychiatric, psychological, familial, or
geographical condition, which in the judgment of the sponsor-project leader may
interfere with the project or affect patient compliance (ICTRP)
non disponible
Critères d'évaluation principaux et secondaires
Focal Outcome Measure (FOM) 1 of pilot study: Proportion of patients for whom the molecular Tumor Board (mTB) considers a different treatment option;FOM 2 of pilot study: Investigation whether the treating oncologist feels better supported by the mTB recommendation considers the additional biological tumor information than by the standard of care where such information is not considered.;FOM 3 of pilot study: Investigation of different treatment decisions by the patient and the treating oncologist.;FOM 4 of pilot study: Preliminary estimate of the actual patient benefit of the intervention in terms of a number of patient-relevant outcomes. (ICTRP)
non disponible
Date d'enregistrement
non disponible
Inclusion du premier participant
non disponible
Sponsors secondaires
Tumor Profiler Center Switzerland (ICTRP)
Contacts supplémentaires
Viola Heinzelmann-Schwarz, Prof.;Maren S Vogel, PhD;Viola Heinzelmann-Schwarz, Prof, maren.vogel@usb.ch; viola.heinzelmann@usb.ch, +41 61 3284203;+41 (0)61 265 58 83, University Hospital Basel, Head Women's Hospital, (ICTRP)
ID secondaires
Swiss-GO-08/ OV Precision (ICTRP)
Résultats-Données individuelles des participants
non disponible
Informations complémentaires sur l'essai
https://clinicaltrials.gov/ct2/show/NCT06466382 (ICTRP)
Résultats de l'essai
Résumé des résultats
non disponible
Lien vers les résultats dans le registre primaire
non disponible